The company is substantially boosted its development of an new treatment for cardiac amyloidosis, employing the compound. Initial patient results indicates potential outcomes for patients diagnosed by the serious https://biotech493942.blog2learn.com/89753522/bridgebio-advances-attr-cm-management-using-the-drug